Antiretroviral Treatment Reduces Spread of HIV Among Injection Drug Users

Highly active antiretroviral therapy (HAART) not only benefits the health of individuals with HIV and a history of injection drug use but also reduces transmission of the virus to others in the community. Using province-wide data from British Columbia from 1996 to 2009, NIDA-funded researchers found a strong association between more extensive treatment with HAART and reductions in new HIV diagnoses per year, as well as decreased viral load in patients.

During the study period, as the province expanded HAART coverage more than five-fold as part of its universal health care program, new HIV diagnoses decreased about 50 percent, says lead investigator Dr. Julio Montaner of the British Columbia Centre for Excellence in HIV/AIDS in Canada. The increase in the number of people receiving HAART during the last 5 years of the study was accompanied by a greater decrease in new HIV cases among those with histories of illicit injection drug use than among those with no such history.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below